For news and resources on research on #MPNs, please follow @MPN_RF and sign-up for our monthly e-newsletters at https://t.co/gepwniSC3i. This handle is no longer active.
Our work on structural racism & AML outcomes is out in @BloodJournal! This was a Chicago-wide collab led by Dr. Abraham & @Irumkhan_hem. The big takeaway - structural racism accounts for almost all of the survival disparity in Black & Hispanic pts #leusm
https://t.co/UfTsaM3i8G
Congrats to @jyoti_nangalia and her research team on this exciting publication! We are proud to be a funder of this important work through a 2019 MPN Challenge award!
👉👉👉Our new paper just out in PubMed: Ruxolitinib re-treatment in patients w/Myelofibrosis 🙌 Acta Haematologica @KargerPublisher | https://t.co/6hDa2QeT9A | @AaronGerds@doctorpemm | #MPNSM
The Voice of the Patient report on MPNs has detailed insights about living with #ET#PV & #MF to help biopharma & @US_FDA keep patient perspective top of mind during drug development & #clinicaltrial design. Check it out at https://t.co/kTjCV2fd3i. #mpnsm
Dr. Richard T. Silver discusses using interferon in the treatment of myeloproliferative neoplasms (MPNs) and a related 3-year global initiative led by the @MPN_RF where he serves as an advisor. Full interview: https://t.co/tx208dTWin (cc: @TargetedOnc) #MPNsm
So great to see these results presented at #ASH21!! Thank you to all researchers, clinicians and patients for doing your part to move research forward toward better options for patients!
ICYMI Monday’s 10:30am #ASH21 oral session hosted by @MPN_RF funded @mullallylab and @mpnlab (formerly funded) was packed with MPN research developments. 3 of the 6 presentations featured work in labs funded by MPNRF! #mpnsm
Thanks to @ASH_hematology and mentorship from @GabyHobbs for the opportunity to present our work on #mpnsm and responses to covid vaccination at #ASH21 !
Exciting trial update at #ASH21 including this overview of the iron metabolism and erythropoiesis from @MPN_RF's previously funded researcher Yelena Ginzburg. Very interested to see further results in this trial of rusfertide in PV patients with high phlebotomy need.
Congrats to @PedsHemeDoc and all MPN Heroes! Thank you for your clinical and research leadership and the compassion you show to #MPN patients and their families!!
Heads up!! TODAY is #GivingTuesday Please support research towards better treatments for #MPN patients by supporting @MPN_RF Be one of the 100 to help us unlock $80,000! https://t.co/Nhiw9XTNk4
Several MPNRF Board Members have committed to personally contribute $80,000 if 100 people donate TODAY. Be 1 of 100 by making a donation at https://t.co/6ZRQ4DA6i5. Together, we advance MPN research! #MPNsm#GivingTuesday
Several MPNRF Board Members have committed to personally contribute $80,000 if 100 people donate TODAY. Be 1 of 100 by making a donation at https://t.co/6ZRQ4DA6i5. Together, we advance MPN research! #MPNsm#GivingTuesday
Today we approved a new treatment for polycythemia vera, a rare blood disease that causes the overproduction of red blood cells. This is the first FDA-approved option that patients with this disease can take regardless of their previous treatment history. https://t.co/EnXPmM1i0D
PV patients. Check out these 10 Quick Facts regarding RoPEG INF (Besremi) for PV. 10 facts MPN patients need to know about FDA approval of Ropegylated int... https://t.co/m5HjqP8rIk via @YouTube@doctorpemm@jjkiladjian@harrisoncn1 @UTHealthSAMDA #mpnsm
We are excited to announce our 2021 MPN Challenge awards! Each of the 5 research projects will be funded up to $200K over 2 years. 🔬 Learn about the researchers & the focus of their research at https://t.co/xe3uzW8ILV. We are grateful to @LLSusa for co-funding a grant. #MPNSM
Why do some people with ET, PV & Primary MF respond dramatically to interferon while others have no benefit, or become resistant over time? A new report on our 3-year Interferon Initiative provides insights. Learn more at https://t.co/x8jBMl4Icv #MPNsm#MPN